Researchers at Stanford Medicine reported in mice that a two-headed experimental “molecular glue” strategy can eradicate aggressive human lymphoma tumors by converting a cancer growth driver into an intrinsic kill switch. The compound, called TCIP3, does not act as a straightforward inhibitor or destruction agent for the driver protein. Instead, the approach forces a functional change in how the targeted proteins behave inside malignant cells, producing a tumoricidal effect. The preclinical findings were framed around overcoming limitations of conventional targeted modalities by reprogramming protein interactions. For drug developers, the work adds to the growing molecular-glue portfolio while reinforcing demand for mechanisms that can selectively rewire otherwise hard-to-target oncogenic networks.